Coca-Cola “very focused” on GLP-1 weight-loss drugs
The company said it would “continue to monitor this space” but highlighted the strength of its low- and no-calorie portfolio.
The company said it would “continue to monitor this space” but highlighted the strength of its low- and no-calorie portfolio.